Contineum Therapeutics, Inc. (CTNM) Stock Overview
Explore Contineum Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Contineum Therapeutics, Inc. (CTNM)
Key Financials
Key Financials
Market Cap
518.2M
P/E Ratio
-7.23
EPS (TTM)
$-1.95
ROE
-0.27%
CTNM Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Contineum Therapeutics, Inc. (NASDAQ: CTNM) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Contineum Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CTNM on the NASDAQ shows an RSI of 49.16, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $23.14 for the NASDAQ listing.
Key metrics behind Contineum Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -7.23 and a market capitalization of 518.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CTNM on the NASDAQ.